Wednesday, July 29, 2015

New Development in Monoclonal Antibodies!

A recent development in monoclonal antibodies for Alzheimer's was announced in an article by FierceBiotech Research. Scientists at NYU Langone Medical Center's Center for Cognitive Neurology is conducting a study that suggests monoclonal antibodies designed to specifically target misfolding proteins in soluble, aggregated states, could be ideally used to treat neurodegenerative diseases such as Alzheimer's, ALS, Parkinson's, and Huntington's.

Monoclonal antibodies are now used for treatments of a wide array of diseases, especially cancer, autoimmune, and inflammatory diseases and the studies are only expanding. With the market for monoclonal antibodies exploding to an estimated $31.7 billion by 2017, don’t miss out on the opportunity to discover the future of antibody engineering at the upcoming IBC’s Antibody Engineering & Therapeutics event.

This is the most trusted antibody engineering event in the industry where you will not only connect with over 700 antibody industry experts, but also learn about the latest antibody science and applications to expand your pipeline of antibody therapeutics.

Hear from the below experts this December 7-10  in San Diego, CA to uncover more about monoclonal antibodies and recent developments for non-cancer and orphan indications.

  • Trudi Veldman, Ph.D.., Senior Director Biologics Generation, AbbVie Bioresearch Center
  • Patrik Maurer, Ph.D., Head Research and Preclinical Development, ESBATech, a Novartis Company, Switzerland
  • Jos Raats, Ph.D., CEO, ModiQuest B.V., The Netherlands
  • Mary Keir, Ph.D., Scientist, Immunology, Tissue Growth and Repair (ITGR), Diagnostic Discovery, Genentech, Inc.
  • Ahuva Nissim, Ph.D., Reader in Antibody and Therapeutic Engineering, Biochemical Pharmacology, Queen Mary University, United Kingdom
  • Ulrich Wuellner, Ph.D., Associate Director, Discovery Research, Covagen AG, Switzerland
  • Chung-Ming Hsieh, D.SC., Associate Director, Biologics, AbbVie Bioresearch Center
  • James Larrick, M.D., Ph.D., Managing Director and Chief Medical Officer, Panorama Research Institute and Velocity Pharmaceutical Development
  • Bo Yu, Ph.D., Co-founder and CSO, Larix Bioscience, LLC
  • Wendy Williams Ph.D., Scientist II, Antibody Discovery and Protein Engineering, MedImmune, United Kingdom
  • Vaughn Smider, M.D., Ph.D., Assistant Professor, Department of Cell and Molecular Biology, The Scripps Research Institute
  • Mark De Boer, Ph.D., CEO, Fast Forward Pharmaceuticals BV, The Netherlands
  • Peter Ulrichts, Ph.D., Principal Scientist, arGEN-X BVBA, Belgium

Download the Brochure for the Full Session and Speaker Details.

Accelerate your antibody research, discovery efforts and clinical programs at the most comprehensive event for comparing and contrasting engineering, discovery and development strategies for different antibody modalities.

Plus, take advantage of an extra $100 off the current rate with code D15172BLOG - Register Now!

Share this article with your social network, just click below to share now!

No comments :

Post a Comment